For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Vyndamax and Tafamidis meglumine represents a significant advancement . These novel therapies preserve the transthyretin protein, slowing its damaging build-up and alleviating the severity of the illness. People are now seein… Read More